• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

TearLab prices $35.1 mil public offering of common stock

Article

 

San Diego-TearLab Corp. announced the pricing of an underwritten public offering of 2,600,000 shares of its common stock at a price to the public of $13.50 per share for gross proceeds of $35.1 million.

Net proceeds from the sale of the shares will be approximately $32.6 million.  TearLab has also granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover overallotments.

TearLab plans to use the net proceeds from this offering for commercialization of its products, research and development, working capital, and other general corporate purposes. The offering is expected to close on or about July 30, subject to the satisfaction of customary closing conditions.

Related Videos
R Tracy Williams, OD, FAAO, details his experience as a sports team optometrist
Andy Morgenstern, OD, FAAO, FNAP chats with Optometry Times
R Tracy Williams, OD, FAAO with Optometry Times
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
Bonnie An Henderson, MD, highlights key takeaways of the 2024 EnVision Summit, including diversity and family inclusion
© 2024 MJH Life Sciences

All rights reserved.